AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

The FDA has approved AbbVie’s supplemental new drug application for Rinvoq (upadacitinib) to treat inflammatory bowel disease ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...

In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement ...

AbbVie said its Rinvoq showed superiority over the company’s previous bestselling drug Humira in a head-to-head trial. Results showed that 43% of patients compared to 22% of patients on Humira ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...